MarketScreener Homepage > Equities > Australian Stock Exchange > ResApp Health Limited RAP AU000000RAP5

Report

End-of-day quote Australian Stock Exchange - 11/26
0.09	AUD		-1.10%

04/05

RESAPP HEALTH : Morgans rates RAP as Add

2019

RESAPP HEALTH : 2019 Letter to Shareholders

2017

RESAPP HEALTH : Updated Corporate Governance Policies

News

Most relevant

Official Publications

Sector news

Most relevant news about RESAPP HEALTH LIMITED

04/05	RESAPP HEALTH : Morgans rates RAP as Add	AQ
2019	RESAPP HEALTH : 2019 Letter to Shareholders	PU
2017	RESAPP HEALTH : Updated Corporate Governance Policies	PU
2017	RESAPP HEALTH (ASX : RAP) talks study results and clinical trials	FI
2017	RESAPP HEALTH : Update on Field Evaluation by Médecins Sans Frontières/Doctors W..	PU
2017	RESAPP HEALTH : Update on Field Evaluation by Medecins Sans Frontieres	PU
2017	RESAPP HEALTH : SMARTCOUGH-C Study and Paediatric Clinical Strategy Update	PU
2017	RESAPP HEALTH : Appendix 4E - Preliminary Final Report	PU
2017	RESAPP HEALTH : Dr Philip Currie Joins ResApp's Scientific Advisory Board	PU
2017	RESAPP HEALTH : Dr Philip Currie Joins ResApp's Scientific Advisory Board	PU
2017	RESAPP HEALTH : Receives R&D Tax Incentive Cash Refund for FY16	PU
2017	RESAPP HEALTH : Reports Preliminary Top-line Results from SMARTCOUGH-C Study for..	PU
2017	RESAPP HEALTH : Change of Director's Interest Notice	PU
2017	RESAPP HEALTH : Investor Conference Call	PU
2017	RESAPP HEALTH : Appendix 4C - Quarterly Jun 2017	PU
2017	RESAPP HEALTH : Investor Presentation	PU
2017	RESAPP HEALTH : Morgans Initiates Research Coverage	PU
2017	RESAPP HEALTH : Release of Restricted Securities	PU
2017	RESAPP HEALTH : Announces Completion of Enrolment in SMARTCOUGH-C Study	PU
2017	RESAPP HEALTH : Completion of Enrolment in SMARTCOUGH-C Study	PU
2017	RESAPP HEALTH : Presentation at ASX Spotlight Investor Conference	PU
2017	RESAPP HEALTH : Provides SMARTCOUGH-C May Study Update	PU
2017	RESAPP HEALTH : ResAppDx to be Formally Evaluated by Médecins Sans Frontières/Do..	PU
2017	RESAPP HEALTH : ResAppDx to be Formally Evaluated by Doctors Without Borders	PU
2017	RESAPP HEALTH : Extension of CEO and Managing Director's Contract	PU
2017	RESAPP HEALTH : Licenses Additional Pneumonia Diagnostic Tool from UniQuest	PU
2017	RESAPP HEALTH : Appendix 4C - Quarterly Mar 2017	PU
2017	LNK : Change of Perth Address for Shareholder Purposes	PU
2017	RESAPP HEALTH : Extends SMARTCOUGH-C Study	PU
2017	RESAPP HEALTH : to Present at Upcoming Conferences in March	PU
2017	RESAPP HEALTH (ASX : RAP) discusses revolutionary diagnostic app for respiratory..	FI
2017	RESAPP HEALTH : Appendix 3B	PU
2017	RESAPP HEALTH : Appendix 4C - Quarterly Dec 2016	PU
2017	RESAPP HEALTH : Announces Expanded Research Collaboration with MGH	PU
2017	RESAPP HEALTH : Announces Expanded Research Collaboration with Massachusetts Gen..	PU
2016	RESAPP HEALTH : Appendix 3B & Section 708A Notice	PU
2016	RESAPP HEALTH : Patersons Securities Initiates Research Coverage	PU
2016	RESAPP HEALTH : Receives Institutional Review Board Approval at Texas Children's..	PU
2016	RESAPP HEALTH : Receives Institutional Review Board Approval at Massachusetts Ge..	PU
2016	RESAPP HEALTH : Change of Director's Interest Notice x 4	PU
2016	RESAPP HEALTH : Appendix 3B	PU
2016	RESAPP HEALTH : Receives IRB Approval at Massachusetts General	PU
2016	RESAPP HEALTH : Confirmation of Change of Auditor	PU
2016	RESAPP HEALTH : Appendix 4C - Quarterly Sep 2016	PU
2016	RESAPP HEALTH : Appendix 3B & Section 708A Notice	PU
2016	RESAPP HEALTH : Receives First Institutional Review Board Approval for SMARTCOUG..	PU
2016	RESAPP HEALTH : Receives First Institutional Review Board Approval	PU
2016	RESAPP HEALTH : Investor Presentation	PU
2016	RESAPP HEALTH : Appendix 3B & Section 708A Notice	PU
2016	RESAPP HEALTH : Announces Further Positive Results from Adult Clinical Study	PU
2016	RESAPP HEALTH : Further Positive Results From Adult Clinical Study	PU
2016	RESAPP HEALTH : Appendix 3B & Section 708A Notice	PU
2016	RESAPP HEALTH : Change in substantial holding	PU
2016	RESAPP HEALTH : Change of Auditor	PU
2016	RESAPP HEALTH : Appendix 4C - Quarterly Jun 2016	PU
2016	RESAPP HEALTH : Bioshares Biotech Summit Presentation	PU
2016	RESAPP HEALTH : Appendix 3B	PU
2016	RESAPP HEALTH : Update on US Clinical Study	PU
2016	RESAPP HEALTH : Positive Preliminary Results from Adult Clinical Study	PU
2016	RESAPP HEALTH : Release of Restricted Securities	PU
2016	RESAPP HEALTH : Appendix 3B	PU
2016	RESAPP HEALTH : Provides Australian Adult Study Enrolment Update	PU
2016	RESAPP HEALTH : Appendix 3B - Exercise of Options	PU
2016	RESAPP HEALTH : Appendix 3B - Release of Restricted Securities	PU
2016	RESAPP HEALTH : Investor Presentation	PU
2016	RESAPP HEALTH : Appendix 4C - Quarterly Mar 2016	PU
2016	RESAPP HEALTH : Appendix 3B and Issue of Cleansing Prospectus	PU
2016	RESAPP HEALTH : Completes Oversubscribed $12.5 Million Capital Raising to Expand..	PU
2016	RESAPP HEALTH : Completes Oversubscribed $12.5M Capital Raising	PU
2016	RESAPP HEALTH : Provides Updated Paediatric Clinical Study Results	PU
2016	RESAPP HEALTH : Director Resignation and Appendix 3Z	PU
2016	RESAPP HEALTH : talks development of digital healthcare solutions	FI
2016	RESAPP HEALTH : Change of Director's Interest Notice	PU
2016	RESAPP HEALTH : Presentation at the ASX CEO Sessions	PU
2016	RESAPP HEALTH : Terms of Executive Appointment	PU

1 2 Next

Upcoming event on RESAPP HEALTH LIMITED

03/04/21

Erstes Halbjahr 2021 Ergebnisveröffentlichung (geplant)

Company calendar

Sector

Technology
	Software & IT Services
		Software & IT Services
			Software
				Enterprise Software